View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 12, 2022

FDA grants breakthrough device designation for T2 Biosystems’ T2Lyme Panel

The T2Lyme Panel runs on the FDA-cleared T2Dx Instrument and detects the bacteria that cause Lyme disease.

The US Food and Drug Administration (FDA) has granted breakthrough device designation for T2 Biosystems’ T2Lyme Panel.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

A direct-from-blood molecular diagnostic test, the T2Lyme Panel has been designed to detect the Borrelia burgdorferi, Borrelia afzelii and Borrelia garinii bacteria, which cause Lyme disease, directly from a patient’s blood.

It runs on the FDA-cleared T2Dx Instrument and has been developed to support early diagnosis of the disease.

Early diagnosis allows appropriate treatments to be provided quickly, which helps to prevent or reduce the complications and significant costs associated with the disease.

According to preclinical data, the device provides superior accuracy compared to other diagnostics used for detecting Borrelia infections in patients that are suspected of having Lyme disease.

T2Biosystems chairman and CEO John Sperzel said: “We are pleased with the FDA’s decision to grant breakthrough device designation for the T2Lyme Panel, as it brings us one step closer to providing clinicians with a valuable tool to detect Lyme disease earlier.

“Similar to the value proposition of our sepsis panels, we believe the T2Lyme Panel will allow clinicians to ensure patients receive the appropriate therapy faster and prevent the negative impact of a delay in delivery of appropriate therapy and the overuse of antibiotics.”

The company stated that the latest move follows the issuance of a patent number that covers the T2Lyme Panel by the US Patent and Trademark Office.

At present, there are no sensitive FDA-approved diagnostic tests to detect the disease in its early stages.

Nearly 476,000 people are annually diagnosed and treated for Lyme disease in the US, according to the US Centers for Disease Control and Prevention (CDC).

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network